Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors - Contact Levi & Korsinsky
Portfolio Pulse from
A class action lawsuit has been filed against Intellia Therapeutics (NTLA) alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
March 26, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics announced halting NTLA-3001 research and reducing workforce by 27%, leading to a stock price decline and potential legal action from shareholders.
The lawsuit and company's announcement of research discontinuation directly impact NTLA's stock price, signaling potential negative investor sentiment and financial challenges.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100